Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Myocardial Doppler tissue velocity improves following myocardial gene therapy with VEGF-A(165) plasmid in patients with inoperable angina pectoris
Autore:
Sylven, C; Sarkar, N; Ruck, A; Drvota, V; Y-Hassan, S; Lind, B; Nygren, A; Kallner, G; Blomberg, P; van der Linden, J; Lindblom, D; Brodin, LA; Islam, KB;
Indirizzi:
Huddinge Univ Hosp, Karolinska Inst, Dept Cardiol, Novum, S-14186 Huddinge, Sweden Huddinge Univ Hosp Huddinge Sweden S-14186 vum, S-14186 Huddinge, Sweden Huddinge Univ Hosp, Karolinska Inst, Dept Clin Physiol, Novum, S-14186 Huddinge, Sweden Huddinge Univ Hosp Huddinge Sweden S-14186 vum, S-14186 Huddinge, Sweden Huddinge Univ Hosp, Karolinska Inst, Dept Thorac Surg, Novum, S-14186 Huddinge, Sweden Huddinge Univ Hosp Huddinge Sweden S-14186 vum, S-14186 Huddinge, Sweden Huddinge Univ Hosp, Karolinska Inst, Gene Therapy Ctr, Novum, S-14186 Huddinge, Sweden Huddinge Univ Hosp Huddinge Sweden S-14186 vum, S-14186 Huddinge, Sweden
Titolo Testata:
CORONARY ARTERY DISEASE
fascicolo: 3, volume: 12, anno: 2001,
pagine: 239 - 243
SICI:
0954-6928(200105)12:3<239:MDTVIF>2.0.ZU;2-J
Fonte:
ISI
Lingua:
ENG
Soggetto:
ECHOCARDIOGRAPHY; DISEASE;
Keywords:
plasmid; VEGF; human; coronary artery disease; thoracotomy; Doppler; perfusion;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
9
Recensione:
Indirizzi per estratti:
Indirizzo: Sylven, C Huddinge Univ Hosp, Karolinska Inst, Dept Cardiol, Novum, C188, S-14186 Huddinge, Sweden Huddinge Univ Hosp C188 Huddinge Sweden S-14186 uddinge, Sweden
Citazione:
C. Sylven et al., "Myocardial Doppler tissue velocity improves following myocardial gene therapy with VEGF-A(165) plasmid in patients with inoperable angina pectoris", CORON ART D, 12(3), 2001, pp. 239-243

Abstract

Background Myocardial tissue velocity and perfusion were studied in patients with severe angina pectoris following gene therapy by intramyocardial injection of phVEGF-A(165) via thoracotomy. Plasma concentrations of VEGF-A increased postoperatively. Two months after treatment anginal status and myocardial tissue velocity improved and perfusion showed a tendency to improve. Tissue velocity imaging appears to be a sensitive, objective method for detecting changes in myocardial function following gene therapy. Objective To study effects on myocardial tissue velocity and perfusion in patients with angina pectoris following intramyocardial injection of phVEGF-A(165) via thoracotomy. Design Open label, phase I/II. Methods Six patients with Canadian Cardiovascular Society (CCS) angina pectoris functional Glass III - IV and with major defects at adenosine stress single-photon emission computerized tomography (SPECT) were studied. In addition to SPECT, coronary angiography and dobutamine stress echocardiographywith tissue Doppler velocity imaging were performed before and two months after gene transfer. Results Plasma concentrations of VEGF-A increased 2 to 3 times (P < 0.04) over baseline from 2 to 14 days after injection with normalization after 4 weeks. The CCS class improved about 40%, from 3.3 +/- 0.2 to 2.0 +/- 0.3 (P< 0.02) and nitroglycerine consumption decreased 30 - 40%, from 44 +/- 17 to 15 +/- 5 tablets per week (P < 0.05). The maximal systolic myocardial tissue velocity increased in all patients about 25% (P < 0.02) but did not reach the reference range. Myocardial perfusion at SPECT improved in four of the six patients. Conclusions Anginal status, myocardial tissue velocity and perfusion can be improved by phVEGF-A(165) intramyocardial injection. Tissue velocity imaging appears to be a sensitive, objective method for detecting changes in myocardial function following gene therapy. Coron Artery Dis 12:239-243 (C) 2001 Lippincott Williams & Wilkins.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 03/12/20 alle ore 15:27:30